This partnership enables BaseClear to offer an end-to-end automated workflow, covering everything from initial sample intake and genomic extraction to data delivery. The collaboration is designed to support industries ranging from cell and gene therapy to industrial biotechnology, where massive scale and cost efficiency are often the primary barriers to progress. Researchers can now utilize this infrastructure for complex tasks like metagenomics, single-cell analysis, and large-scale transcriptomics.

Beyond general research support, the adoption of the UG200 platform is central to BaseClear’s role in Basecamp Research’s Trillion-Gene Atlas project. This initiative seeks to model biological data at an unprecedented scale, requiring the high-throughput capabilities that Ultima’s architecture provides. According to BaseClear CEO Roel Sterken, the new platform sets a benchmark for data integrity and economic feasibility, allowing organizations to accelerate decision-making in clinical research and therapeutic development. BaseClear officially opened its Ultima-enabled service offerings to the global market in mid-July 2026.